换一批
换一批Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.
作者：
主题词
抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);细胞系, 肿瘤(Cell Line, Tumor);细胞存活(Cell Survival);I类磷脂酰肌醇3-激酶类(Class I Phosphatidylinositol 3-Kinases);结肠肿瘤(Colonic Neoplasms);培养基, 条件性(Culture Media, Conditioned);加贝酯(Gabexate);人类(Humans);突变(Mutation);肿瘤侵润(Neoplasm Invasiveness);新生血管化, 病理性(Neovascularization, Pathologic);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);蛋白酶抑制药(Protease Inhibitors);原癌基因蛋白质类(Proto-Oncogene Proteins);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);原癌基因蛋白质类p21(ras)(Proto-Oncogene Proteins p21(ras));治疗结果(Treatment Outcome);ras蛋白质类(ras Proteins)
DOI
10.1371/journal.pone.0041347
PMID
22911782
发布时间
2021-10-21
- 浏览40
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
